Scienture Holdings, Inc.
$ 0.50
-6.05%
26 Dec - close price
- Market Cap 20,441,400 USD
- Current Price $ 0.50
- High / Low $ 0.54 / 0.50
- Stock P/E 0.67
- Book Value 3.57
- EPS 0.75
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.24 %
- 52 Week High 6.56
- 52 Week Low 0.46
About
None
Analyst Target Price
N/A
Quarterly Earnings
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-08-18 | 2025-04-21 | 2025-03-25 | 2024-11-29 | 2024-07-22 | 2024-04-24 | 2024-03-25 | 2023-10-25 | 2023-08-21 | 2023-05-16 | 2023-03-28 | 2022-11-08 |
| Reported EPS | -0.4752 | -0.3251 | -0.8185 | -1.3411 | -1.304 | 20.4928 | -12.9457 | -4.571 | -2.8991 | -1.0108 | -1.4896 | -0.9146 |
| Estimated EPS | None | None | None | None | None | None | None | None | None | None | None | None |
| Surprise | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jul 2024 | Mar 2024 | |
|---|---|---|
| Payment Date | 2024-07-24 | 2024-03-22 |
| Amount | $1.5 | $8.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SCNX
2025-12-23 10:09:41
Scienture Holdings, Inc. announced that its REZENOPY naloxone HCl nasal spray, FDA-approved and set to be the highest-strength naloxone product at 10 mg, will be commercially available in early Q2 2026, with wholesale distribution starting in Q1 2026. Despite impressive gross profit margins of 88.48%, the micro-cap company, with a valuation of $23.18 million, is not yet profitable and faces challenges such as quickly burning through cash and a low current ratio. This launch represents a significant opportunity for Scienture in the rapidly growing U.S. naloxone market, which reached $154 million in annual sales by September 2025.
2025-12-23 10:08:44
SCIENTURE HOLDINGS, INC. has provided an update on the commercial launch of REZENOPY® (naloxone HCl) Nasal Spray 10 mg, the highest-strength naloxone product approved by the FDA. The company expects the product to be ready in Q1 2026, with commercial availability beginning in early Q2 2026. This product aims to address the critical need for a more potent naloxone for emergency opioid overdose situations, especially those involving multiple or powerful opioids.
2025-12-23 07:09:12
SCIENTURE HOLDINGS, INC. has provided an update on the commercial launch of REZENOPY® (naloxone HCl) Nasal Spray 10 mg, an FDA-approved high-strength opioid overdose treatment. The company expects the product to be ready for wholesale channel loading in Q1 2026, with commercial availability beginning in early Q2 2026, addressing a critical unmet need in emergency overdose response. REZENOPY® is designed to be more effective against potent opioids and for patients requiring multiple doses of lower-strength naloxone.
2025-12-22 13:09:12
Scienture Holdings Inc. (SCNX) announced an update on the commercial launch of Rezenopy®, an FDA-approved high-strength naloxone HCl opioid overdose emergency treatment. The company expects Rezenopy to be commercially available in early Q2 2026.
2025-12-22 13:09:12
Scienture (SCNX) is preparing to launch REZENOPY® (naloxone HCl) Nasal Spray 10 mg, the highest-strength FDA-approved naloxone product, in Q2 2026. The company secured exclusive U.S. commercialization rights in March 2025 for the product, which received FDA approval in April 2024. This high-strength nasal spray is designed to address opioid overdoses, targeting a U.S. market with annual sales of $154 million and 9.3 million units.
2025-12-10 13:09:29
SCIENTURE (NASDAQ: SCNX) announced a strategic collaboration with BlinkRx to enhance national patient access to Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium. Arbli™ is anticipated to be available on the BlinkRx platform in Q1 2026, targeting a U.S. losartan market valued at $245 million annually with 71 million prescriptions. BlinkRx's platform is reported to increase therapy initiation by 52% and extend medication persistence by 40%, potentially improving patient starts, duration, and affordability for those requiring suspension formulations.
